Novocure announces results from Phase 2 PANOVA-4 trial met primary endpoint

Novocure (NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields, TTFields, therapy concomitant with atezolizumab, gemcitabine and nab-paclitaxel as a first-line treatment for metastatic pancreatic ductal adenocarcinoma, mPDAC. PANOVA-4 met its pre-specified primary endpoint, achieving a statistically significant improvement in disease control rate, DCR, compared to the DCR reported in the Phase 3 MPACT study used as the historical control. The DCR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac was 74.4% compared to a DCR of 48% in patients receiving gem/nab-pac alone in the historical control. Secondary endpoints in PANOVA-4 include objective response rate and overall survival. The ORR in patients treated with TTFields therapy concomitantly with atezolizumab and gem/nab-pac was 34.6% and median OS was 9.7 months. Additional secondary endpoints were progression-free survival, one-year survival rate, progression-free survival at six months, duration of response, and rate of patients with treatment emergent adverse events.